anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to human serine/threonine kinase ULK3 and its ability to regulate GLI transcription factors; mediators of SHH signaling. This disclosure demonstrates that ULK3 enhances endogenous and over-expressed GLI1 and GLI2 transcriptional activity in cultured cells, and ULK3 alters subcellular localization of GLI1. According to this disclosure ULK3 is an autophosphorylated kinase and phosphorylates GLI proteins in vitro. A peptide sequence in GLI1 C-terminus that is phosphorylated by ULK3 is provided in this disclosure. ULK3 catalytical activity is shown to be crucial for its function in SHH pathway. This disclosure shows that serine/threonine kinase ULK3 is involved in the SHH pathway as a positive regulator of GLI proteins. Furthermore, a therapeutic method in SHH dependent human disorders is disclosed by pharmacological inhibition of ULK3 kinase activity. Identification of ULK3 substrate sequence in GLI1 allows the design of peptide-based modulators of its kinase activity.
Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is a global health challenge with significant morbidity and mortality. Iron deficiency, including non-anaemic iron deficiency (NAID), has been identified as a potential comorbid in COPD, affecting patient outcomes and disease severity. This study aimed to investigate the prevalence and impact of iron deficiency on the severity and clinical outcomes in COPD patients.
METHODS: In this descriptive cross-sectional study, 289 individuals diagnosed with COPD were enrolled and underwent comprehensive medical assessments, including haematological tests and spirometry from December 2019 to December 2023. The study focused on measuring iron levels, exercise capacity, and exacerbation frequency, comparing iron-deficient and non-iron-deficient groups.
RESULTS: The study found that 46.7% of participants had iron deficiency. Those with iron deficiency showed significantly lower exercise capacity as measured by the six-minute walk distance and experienced a higher frequency of yearly COPD exacerbations. However, no significant differences were observed in airflow limitation and the overall quality of life between the iron-deficient and non-iron-deficient groups.
CONCLUSIONS: The findings suggest that iron deficiency, particularly NAID, is associated with a more severe progression of COPD, characterized by reduced exercise capacity and increased exacerbation frequency. These results highlight the importance of considering iron deficiency in the management of COPD to potentially improve patient outcomes.
The safety assessment in children and adolescents is based on the Week 24 analysis of the single-arm, Phase 2 trial TMC125-C213 in which 101 antiretroviral treatment-experienced HIV-1 infected subjects 6 years to less than 18 years of age and weighing at least 16 kg received INTELENCE in combination with other antiretroviral agents [see Clinical Studies (14.2)]. The frequency, type and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adult subjects, except for rash which was observed more frequently in pediatric subjects. The most common adverse drug reactions in at least 2% of pediatric subjects were rash and diarrhea. Rash (greater than or equal to Grade 2) occurred in 15% of pediatric subjects. In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy. Rash was self-limiting and generally resolved within 1 week on continued therapy. The discontinuation rate for rash was 4%. Rash including serious (Grade 3 or 4) events and discontinuations were more frequently observed in female subjects compared to male subjects.
Polycystic ovary syndrome (PCOS) is one of the most common disorders among women in modern societies. A variety of factors can contribute to the development of PCOS. These women often exhibit high insulin resistance (IR), hyperandrogenism, irregular periods, and infertility. Dysbiosis of the gut microbiota (GMB) in women with PCOS has attracted the attention of many researchers. Porphyromonas spp., B. coprophilus, and F. prausnitzii are found in higher numbers in the gut of women with PCOS. Short-chain fatty acids (SCFAs), produced by the intestinal microbiota through fermentation, play an essential role in regulating metabolic activities and are helpful in reducing insulin resistance and improving PCOS symptoms. According to studies, the bacteria producing SCFAs in the gut of these women are less abundant than in healthy women. The effectiveness of using probiotic supplements has been proven to improve the condition of women with PCOS. Daily consumption of probiotics improves dysbiosis of the intestinal microbiome and increases the production of SCFAs.
Lung transplantation is the less common solid organ transplant performed; it is the treatment of choice for end stage lung disease. Lung transplantation is "problematic" for a number of reasons: low graft availability, high waitlist mortality and unsatisfactory survival. Acute rejection, occurring days to months after surgery, has been identified as one of the main risk factors for the development of chronic rejection: in the first five years after lung transplantation, chronic rejection is the major cause of graft failure, morbidity and mortality. A deep knowledge of the immunological scenarios associated with lung graft tolerance could allow selectively switch-off T-cells involved in the rejection process. The researches, preliminary demonstrated the central role of immunological checkpoints in the development of acute rejection and its evolution towards chronic rejection. The aim of this study is the identification of markers that could be associated with the establishment of lung graft tolerance.

The project is articulated into two parts: a retrospective and a prospective section. The retrospective section is constituted by a cross-sectional study of immune checkpoints on lungs explanted during lung re-transplantation for chronic rejection (cohort 1). In addition, the retrospective section includes a retrospective cohort study of immune checkpoints on specimens from transbronchial lung biopsies of participants who received lung transplantation and have 3 years of follow-up (cohort 2). The prospective section is a cohort study of immune checkpoints on specimens from transbronchial lung biopsies and gene expression analysis on immune cells purified from bronchoalveolar lavage; participants will be subjects receiving the lung transplantation during the first year of recruitment and followed for one year (cohort 3).
The invention relates to a bacteriostatic liquid, in particular to a bacteriostatic liquid prepared by extracting pure Chinese medicinal materials as raw materials. The invention also relates to a preparation method and application of the antibacterial liquid. The invention aims to provide bacteriostatic liquid for treating skin diseases, which is prepared by extracting pure traditional Chinese medicines as raw materials, does not obstruct normal respiratory metabolism of skin, can ensure that medicines contained in the liquid can quickly enter focus parts, and has quick curative effect and high utilization rate. The specific method for preparing the traditional Chinese medicine antibacterial liquid into the spray is to directly fill compressed air in the filled traditional Chinese medicine antibacterial liquid as a propellant so as to form mist to achieve the effect of the spray. Because the invention does not add chemical propellants such as propane, butane or dimethyl ether and the like, the product of the invention is ensured to be nontoxic and harmless to human bodies even if used for a long time. The traditional Chinese medicine antibacterial liquid can be used for treating skin diseases. The invention selects fragrant smell, not only has simple production method and convenient use, but also has no toxicity to human body after use.
A method is provided for predicting that a caregiver will order a blood transfusion during a treatment. The method includes obtaining, on a processor, first data that indicates values for one or more parameters of a characteristic of a peak of a Fourier transform of a continuous photoplethysmographic (PPG) waveform or a continuous electrocardiogram (ECG) waveform or both collected during the treatment. The method further includes applying, on the processor, coefficients to the values for the one or more parameters. The method further includes determining, on the processor, second data that indicates a prediction that the caregiver will order the blood transfusion during the treatment based on applying the coefficients to the values. The method further includes presenting on a display device output data based on the second data. An apparatus is also provided for predicting that the caregiver will order the blood transfusion during the treatment.
FIELD: medicine, biochemistry. SUBSTANCE: invention relates to technology of preparing the liposomal phospholipid carrier of cholesterol. Carrier is liposomal suspension and can interact selectively with human plasma blood lipoprotein of low density and can be used for the directed delivery of cholesterol in peripheral organs and tissues of organism. Method of preparing involves homogenization on plunger homogenizer under high pressure at optimal technological parameters. Method involves dissolving phospholipid and cholesterol in organic solvent, stirring, evaporation and drying followed by hydration, homogenization under high pressure by continuous process, centrifugation of liposomal suspension and sterilizing filtration. The dissolved cholesterol and phospholipids taken at molar ratio = (1:1)-(2:1) were filtered under pressure of inert gas and after evaporation and hydration subjected for cyclic homogenization in the closed contour under pressure 10-120 MPa, at 15-45 C, mainly near the point of phase transition of the corresponding phospholipid, at homogenization cycle number 1-20. Centrifugation is carried out at 1200 rev/min for 40 min, at +5 C. Molar ratio cholesterol/phospholipid in liposomal suspension = (0.9-1.1):(1.5-1.85), mean particle size is 40-200 nm, standard deviation of particles distribution is 20-100 nm. Method involves the use of egg yolk phospholipids and lecithin-enriched fraction of soybeans. Total concentration of phospholipids and cholesterol in liposomal suspension is 1-10 weight/vol.%. Invention can be used in medicine for preparing highly dispersed liposomal preparations showing cytostatic effect on tumors. Also, invention can be used in experimental biology, medicine, in part, in oncology and immunology for the directed delivery of cholesterol to organism tissues. EFFECT: increased output of process. 2 cl, 5 dwg
After having signed informed consent (Day 1-3), eligible subjects who have successfully received first RA-CABG surgery (Day 0) will be screened for enrollment. All subjects (150 patients) will be randomized in a 1:1:1 ratio into 3 groups. Group A will receive oral Nicorandil (5mg tid) monotherapy; Group B will receive oral Diltiazem (180mg qd) monotherapy; and Group C will receive Isosorbide Mononitrate (50mg qd) monotherapy. Three groups will continue intervention treatment for 24 weeks after RA-CABG surgery. All subjects will receive follow-up visits (clinic visit or phone visit) at Week 1, 4, 12, and 24 after surgery.

All subjects will receive first CCTA (or CAG) to evaluate the graft outcome at Week 1 and second CCTA (or CAG) to evaluate the graft outcome at Week 24 after RA-CABG surgery. And all subjects will be evaluated angina relief based on the Canadian Cardiovascular Society (CCS) angina grading and the Seattle Angina Questionnaire. And the time to first major adverse cardiovascular event (MACE), which include all-cause mortality, myocardial infarction, stroke and unplanned revascularization, will be collected. And other safety outcomes will be evaluated, including the rate of hypotension, the proportion of concomitant medications with ACEI/ARB/ARNI drugs and proportion of SAEs and concerned AEs.
PURPOSE:To obtain a poultice capable of sufficiently following the stretch of the skin of e.g. joint and resistant to peeling off from the skin, by spreading a drug containing a tacky adhesive component on a sheet substrate which is stretchable along at least one direction and tearable along a direction perpendicular to the stretchable direction. CONSTITUTION:Plural fiber sheets oriented in longitudinal direction and produced by plural carding machines are laminated one upon another and the laminate is transferred to a template having a prescribed small perforations. Water jet is blasted against the laminate through the perforated template to effect the loosening and entanglement of the fibers and the application of the perforation pattern to the laminate. The obtained laminate is partially bonded or impregnated with an adhesive and dried to obtain a non-woven cloth which is stretchable in transversal direction and easily tearable by hand along the longitudinal orientation of the fibers. The non-woven cloth is used as a substrate and coated with a drug containing a tacky adhesive component (e.g. crosslinked polyacrylic acid copolymer) to obtain the objective poultice.
Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
Participants will be asked to watch videos of neck exercises without performing any exercise. The intervention will take approximately 15 minutes.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmaceutical industry, particularly a drug for glycogen synthesis stimulation in a cardiac muscle. The drug for glycogen synthesis stimulation in the cardiac muscle which represents an alcoholic extract of a porcine and foetal adrenal cortex. A method for glycogen synthesis stimulation in the cardiac muscle by parenteral introduction of the alcoholic extract of the porcine and foetal adrenal cortex in a certain dose. ^ EFFECT: agent effectively stimulates glycogen in the cardiac muscle with no side effects. ^ 2 cl, 2 dwg, 1 tbl
Recent studies have highlighted the potential of Saccharina japonica Polysaccharides (SJPs) in alleviating high-fat diet (HFD)-induced obesity by regulating gut microbiota, which warrants further exploration to elucidate the underlying structure-activity relationship. In this study, five polysaccharide fractions (Sj-T, Sj-T-1, Sj-T-2, Sj-T-3, and Sj-T-4) with different structure characteristics were prepared from S. japonica, and their effects on HFD-induced obesity and gut microbiota composition were investigated using C57BL/6J mice. The results revealed that oral administration of Sj-T considerably suppressed HFD-induced obesity, glucose metabolic dysfunction, and other disordered symptoms. While, Sj-T-2, which has the lowest molecular weight, was the most effective in alleviating HFD-induced obesity and had the second-best effect on improving HFD-induced impaired glucose tolerance among the five SJPs. Supplementation with SJPs significantly modulated HFD-induced gut microbiota dysbiosis both at the phylum and species levels, such as enriching Desulfobacterota and Actinobacteriota, while suppressing the abundance of Bacteroidota. Sj-T also dramatically restored the gut microbiota composition by modulating the abundance of many crucial gut bacterial taxa, including s_Bacteroides_acidifaciens, s_Lachnospiraceae _bacterium, and g_Lachnospiraceae_NK4A136_group. Besides, SJPs also dramatically altered the function of gut microbiota, including many carbohydrate-metabolism enzymes. This study highlights the potential of SJPs in preventing obesity and restoring intestinal homeostasis in obese individuals.
Chemically induced proximity (CIP) refers to co-opting naturally occurring biological pathways using synthetic molecules to recruit neosubstrates that are not normally encountered or to enhance the affinity of naturally occurring interactions. Leveraging proximity biology through CIPs has become a rapidly evolving field and has garnered considerable interest in basic research and drug discovery. PROteolysis TArgeting Chimera (PROTAC) is a well-established CIP modality that induces the proximity between a target protein and an E3 ubiquitin ligase, causing target protein degradation via the ubiquitin-proteasome system. Inspired by PROTACs, several other induced proximity modalities have emerged to modulate both proteins and RNA over recent years. In this review, we summarize the critical advances and opportunities in the field, focusing on protein degraders, RNA degraders and non-degrader modalities such as post-translational modification (PTM) and protein-protein interaction (PPI) modulators. We envision that these emerging proximity-based drug modalities will be valuable resources for both biological research and therapeutic discovery in the future.
The invention relates to a Chinese medicinal granule for treating influenza of cows. The Chinese medicinal granule is prepared from the following components: ephedra herb, bitter apricot seeds, virgate wormwood herb, great burdock achene and pepperweed seeds. The Chinese medicinal granule is prepared by the steps of weighing the components in parts by weight, adding water, decocting the components for 2 times, mixing filtrates, carrying out vacuum concentration, drying, smashing, adding saccharose, granulating, sieving particles, drying, and sieving once again. When in use, the Chinese medicinal granule is mixed with water according to a certain proportion before being fed to the diseased cow. After the diseased cow is fed by the Chinese medicinal granule continuously for a period of time, the disease of the cow can be treated effectively, the appetite can be improved greatly, the rumen motility sound can be enhanced, and the vital energy, the body temperature and the action can return to be normal,. The process for extracting the Chinese medical herbs is simple, the Chinese medicinal granule can be stored for a long time stably, can take effect quickly and can not cause side and toxic effects after being used, and medicine residue does not exist.
The invention discloses a benzyl cyclohexenone derivative and a preparation method and medical application thereof. The benzyl cyclohexenone derivative is a compound in a general formula I. The compound can be individually prepared into a preparation or can be combined with one or more pharmaceutically acceptable carriers to prepare the preparation for administration. The compound can be combined with other antitumor drugs for application, and can also be combined with radiotherapies for application. These antitumor drugs or radiotherapies and the compound disclosed by the invention can be given at the same time or different times. These combination therapies can generate a synergistic effect to improve the treatment effect.
The invention discloses Alpha-glucosaccharase inhibitor: sapodilla plum extractive. Through a vitro experiment and with glucobay as the positive control, the influence of three kinds of extractive of the sapodilla plum to the activity of the Alpha-glucosaccharase is observed, and effective component assessment and the analysis of the dynamic types of the aqueous extract and the fluid extract thereof are performed. A vivo experiment takes a normal mouse as the experimental object, a dose of 2.5 g of crude drugs of sapodilla plum and 3 g/kg of starch is used for gastric irrigation, blood is taken from the tip of the tail of the mouse, blood sugar value is detected, and the influence of the aqueous extract to the starch tolerance is observed. The result shows that the three kinds of extractive of the sapodilla plum have obvious inhibition function to the Alpha-glucosaccharase, with a dose-effect relationship, wherein the aqueous extract has more obvious inhibition effect than the fluid extract and polysaccharide. The dynamic types of the aqueous extract and the fluid extract are all competitive inhibition. The polysaccharide is starch type, and the fluid extract possibly contains hydroxy flavone glycoside substance. The vivo experiment proves that the aqueous extract has the tendency of reducing the blood sugar in one hour after meals.
Hormone replacement therapy (HRT) is considered the gold standard for management of vasomotor and vaginal symptoms of menopause. Vasomotor symptoms of menopause may include hot flashes and diaphoresis that vary in intensity and duration. Other symptoms of menopause can include vaginal atrophy and dryness, leading to dyspareunia and increased risk of infection. These symptoms can be impactful on a woman's life and HRT has data to support its efficacy, however, HRT carries significant risks that are generally well known, including risk of stroke, cardiovascular disease, breast cancer, and venous thromboembolism. These risks were most well characterized by several landmark trials published in the early 2000s. There are several nuances to prescribing HRT that can make doing so complex. These include consideration of cyclic vs continuous administration and of tapering therapy. Additionally, estrogen is available in a variety of dosage forms including injections and transdermal formulations. However, for women with an intact uterus, estrogen will need to be combined with progestin or bazedoxifene (a selective estrogen receptor modulator - SERM), both once daily oral formulations, in order to minimize malignancy risk. Though product preference and considerations of dosing may vary depending on practitioner preference, this brief report aims to clarify some nuances to prescribing or recommending HRT.
Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additional undergo blood sample collection, and CT or MRI throughout the study.